AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25505693 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on lithium
Number of subjects: 356
Study 25505693 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium in combination with quetiapine XR
Number of subjects: 356
Study 25505858 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings
Number of subjects: 138
Study 25505858 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 138
Study 25506426 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpostbariatric abdominoplasty
Number of subjects: 64
Study 25506706 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccine
Number of subjects: 61
Study 25506706 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without clinical malaria)
Number of subjects: 61
Study 25510313 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component physical activity intervention (n = 388) during 12 weeks including improvement of physical education, extracurricular activities, activities at home, and health education lectures.
Number of subjects: 921
Study 25510313 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component physical activity intervention (n = 388) during 12 weeks.
Number of subjects: 921
Study 25510313 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group, n = 533).
Number of subjects: 921
Study 25510385 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspected PE patients (n = 504)
Number of subjects: 1736
Study 25510385 — intervention group
Group type: COMPARATOR
Intervention: RPE patients (n = 1232)
Number of subjects: 1736
Study 25510385 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspected PE patients (both PE and RPE)
Number of subjects: 1736
Study 25510385 — intervention group
Group type: EXPERIMENTAL
Intervention: PE patients (n = 504)
Number of subjects: 1736
Study 25510388 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC-CRM followed by MCC-TT vaccine
Number of subjects: 193
Study 25510388 — intervention group
Group type: COMPARATOR
Intervention: Two MCC-CRM vaccines
Number of subjects: 193
Study 25510388 — intervention group
Group type: COMPARATOR
Intervention: Two MCC-TT vaccines
Number of subjects: 193
Study 25510388 — intervention group
Group type: COMPARATOR
Intervention: MCC-TT followed by MCC-CRM vaccine
Number of subjects: 193
Study 25510395 — intervention group
Group type: COMPARATOR
Intervention: Women with STEMI
Number of subjects: 11986
Study 25510395 — intervention group
Group type: COMPARATOR
Intervention: Women aged <60 with STEMI
Number of subjects: 11986
Study 25510395 — intervention group
Group type: COMPARATOR
Intervention: Women aged 60-69 with STEMI
Number of subjects: 11986
Study 25510395 — intervention group
Group type: COMPARATOR
Intervention: Women aged 70-79 with STEMI
Number of subjects: 11986
Study 25510395 — intervention group
Group type: COMPARATOR
Intervention: Women aged ≥80 with STEMI
Number of subjects: 11986
Study 25510701 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA supplementation
Number of subjects: 0
Study 25510776 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 20
Study 25510920 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone oil tamponade
Number of subjects: 60
Study 25510920 — intervention group
Group type: COMPARATOR
Intervention: Control (fellow unoperated eyes)
Number of subjects: 60
Study 25511105 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin (30 μg kg(-1) day(-1) via intravenous infusion for 24 hours)
Number of subjects: 49
Study 25511105 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 49
Study 25511105 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 49
Study 25511129 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic relaxation suggestion
Number of subjects: 23
Study 25511306 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) or physical activity monitoring program (home or center based)
Number of subjects: 531
Study 25511442 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 110
Study 25511783 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with stages 3-4 renal dysfunction (GFR <60 mL/min/1.73 m(2))
Number of subjects: 146
Study 25511783 — intervention group
Group type: COMPARATOR
Intervention: Patients with stages 1-2 renal dysfunction (normal to mildly impaired)
Number of subjects: 146
Study 25512030 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and trastuzumab neoadjuvant chemotherapy (NC) for 24 weeks, followed by 1 year adjuvant trastuzumab ± hormonal and/or radio-therapy.
Number of subjects: 109
Study 25512030 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and trastuzumab neoadjuvant chemotherapy (NC) for 24 weeks.
Number of subjects: 109
Study 25512030 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab-mediated antibody-dependent cell cytotoxicity (ADCC).
Number of subjects: 109
Study 25512422 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine (600 mg) with bedaquiline (400 mg)
Number of subjects: 0
Study 25512422 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg) with bedaquiline (400 mg)
Number of subjects: 0
Study 25512442 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling about sexual activity after AMI
Number of subjects: 3499
Study 25512630 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir, Pegylated Interferon, and Ribavirin
Number of subjects: 15
Study 25512839 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (three weekly sessions for four weeks)
Number of subjects: 60
Study 25512839 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional occlusal splint therapy (worn for four weeks)
Number of subjects: 60
Study 25512839 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage + Conventional occlusal splint therapy (three weekly sessions for four weeks and occlusal splint worn for four weeks)
Number of subjects: 60
Study 25512839 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone occlusal splint therapy (worn for four weeks)
Number of subjects: 60
Study 25512874 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed loop with diluted insulin aspart (CL_Dil; 20 IU/mL)
Number of subjects: 11
Study 25512874 — intervention group
Group type: COMPARATOR
Intervention: Closed loop with standard aspart (CL_Std; 100 IU/mL)
Number of subjects: 11
Study 25514063 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine users
Number of subjects: 482
Study 25514063 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepine nonusers
Number of subjects: 482
Study 25514102 — intervention group
Group type: EXPERIMENTAL
Intervention: Klinefelter syndrome males
Number of subjects: 73
Study 25514320 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten-dimensional control signals for prosthetic hand shape (three-dimensional translation, 3D orientation, four-dimensional hand shaping)
Number of subjects: 1
Study 25514320 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration with the presence of an object during grasping
Number of subjects: 1
Study 25514427 — intervention group
Group type: EXPERIMENTAL
Intervention: High IL-8 levels (H group, n = 133)
Number of subjects: 468
Study 25514427 — intervention group
Group type: EXPERIMENTAL
Intervention: Low IL-8 levels (L group, n = 335)
Number of subjects: 468
Study 25514427 — intervention group
Group type: EXPERIMENTAL
Intervention: High IL-8 levels (H group)
Number of subjects: 468
Study 25515275 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sleep quality (measured by the Pittsburgh Sleep Quality Index)
Number of subjects: 213
Study 25515841 — intervention group
Group type: EXPERIMENTAL
Intervention: First-pass contrast-enhanced cardiac MR myocardial perfusion imaging during adenosine-induced hyperaemia
Number of subjects: 6
Study 25516773 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol/naproxen (n = 35)
Number of subjects: 105
Study 25516773 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol/CR oxycodone for 24 hours (n = 35)
Number of subjects: 105
Study 25516773 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol/CR oxycodone for 48 hours (n = 35)
Number of subjects: 105
Study 25516774 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once daily
Number of subjects: 219
Study 25516774 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sustained release 75 mg once daily
Number of subjects: 219
Study 25516890 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-2206 at 135 mg weekly and selumetinib at 100 mg once daily
Number of subjects: 0
Study 25517807 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandarin Chinese version of the Leicester Cough Questionnaire (LCQ-MC)
Number of subjects: 144
Study 25518027 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Nutri Plus®
Number of subjects: 10
Study 25518027 — intervention group
Group type: COMPARATOR
Intervention: Dietpro 5i®
Number of subjects: 10
Study 25518864 — intervention group
Group type: EXPERIMENTAL
Intervention: S-100B bulk release
Number of subjects: 48
Study 25518864 — intervention group
Group type: EXPERIMENTAL
Intervention: NSE at 72 hours
Number of subjects: 48
Study 25518864 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Morris-Marshall score and S-100B bulk release
Number of subjects: 48
Study 25519706 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 0
Study 25519706 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 25519705 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensation methods
Number of subjects: 325
Study 25519705 — intervention group
Group type: EXPERIMENTAL
Intervention: Disruption correction
Number of subjects: 325
Study 25519705 — intervention group
Group type: COMPARATOR
Intervention: Friction correction
Number of subjects: 325
Study 25519810 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.01% once daily
Number of subjects: 295
Study 25520557 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis followed by six weeks of self-hypnosis using digital media
Number of subjects: 0
Study 25520557 — intervention group
Group type: COMPARATOR
Intervention: SCD education (Control)
Number of subjects: 0
Study 25520807 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care (patient phone-based self-management support, care management, and guideline dissemination to practices delivered by a plan-level care manager)
Number of subjects: 344
Study 25520807 — intervention group
Group type: COMPARATOR
Intervention: Usual care from their provider
Number of subjects: 344
Study 25520807 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 344
Study 25520807 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 344
Study 25521292 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprachoroidal retinal prosthesis
Number of subjects: 3
Study 25521357 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bevacizumab and first-line paclitaxel with favorable genetic profile (VEGFR-2 rs11133360 and IL-8 rs4073)
Number of subjects: 113
Study 25521357 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bevacizumab and first-line paclitaxel with unfavorable genetic profile (VEGFR-2 rs11133360 and IL-8 rs4073)
Number of subjects: 113
Study 25521398 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib at 45 mg once daily
Number of subjects: 55
Study 25521573 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy (CLE)
Number of subjects: 79
Study 25521573 — intervention group
Group type: EXPERIMENTAL
Intervention: CLE scoring system
Number of subjects: 79
Study 25521639 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic machine preservation (HMP)
Number of subjects: 31
Study 25521639 — intervention group
Group type: COMPARATOR
Intervention: Static cold storage (SCS)
Number of subjects: 31
Study 25521773 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intraoperative dose of morphine
Number of subjects: 219
Study 25522180 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd63-MVA CS (5×10^9 vp)
Number of subjects: 24
Study 25522180 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd63-MVA CS (5×10^10 vp)
Number of subjects: 24
Study 25522180 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd63 CS
Number of subjects: 24
Study 25522809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhosis patients with past obesity
Number of subjects: 905
Study 25522809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhosis patients with tobacco exposure
Number of subjects: 905
Study 25522809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhosis patients with abnormal levels of transaminases
Number of subjects: 905
Study 25522809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhosis patients with diabetes
Number of subjects: 905
Study 25522809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhosis patients with male gender
Number of subjects: 905
Study 25522809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhosis patients with older age
Number of subjects: 905
Study 25523532 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb bioresorbable vascular scaffold (Absorb BVS)
Number of subjects: 51
Study 25523604 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea gel (test group)
Number of subjects: 48
Study 25523604 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (control group)
Number of subjects: 48
Study 25524487 — intervention group
Group type: EXPERIMENTAL
Intervention: T1DM
Number of subjects: 54
Study 25524487 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study 25524686 — intervention group
Group type: EXPERIMENTAL
Intervention: Presurgical levels of circulating CD41(+) PMPs
Number of subjects: 122
Study 25524686 — intervention group
Group type: EXPERIMENTAL
Intervention: Presurgical levels of circulating CD235a(+) RMPs
Number of subjects: 122
Study 25524686 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin (HGB) levels
Number of subjects: 122
Study 25524686 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated partial thromboplastin time (aPTT)
Number of subjects: 122
Study 25524686 — intervention group
Group type: EXPERIMENTAL
Intervention: Model's discriminating ability
Number of subjects: 122
Study 25524795 — intervention group
Group type: EXPERIMENTAL
Intervention: Anamorelin hydrochloride 50 mg once-daily for 12 weeks
Number of subjects: 82
Study 25524795 — intervention group
Group type: COMPARATOR
Intervention: Placebo once-daily for 12 weeks
Number of subjects: 82
Study 25524795 — intervention group
Group type: EXPERIMENTAL
Intervention: Anamorelin
Number of subjects: 82
Study 25524795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 25524800 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab (9 μg/day for the first 7 days and 28 μg/day thereafter) by continuous intravenous infusion over 4 weeks every 6 weeks (up to five cycles)
Number of subjects: 189
Study 25524800 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 189
Study 25525182 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-NOS PET/CT imaging after endotoxin instillation (4 ng/kg)
Number of subjects: 7
Study 25525182 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-NOS PET/CT imaging
Number of subjects: 7
Study 25525693 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative effectiveness research approaches
Number of subjects: 5400
Study 25525693 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross sectional comprehensive outcome assessments
Number of subjects: 5400
Study 25525693 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal assessments
Number of subjects: 5400
Study 25525693 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced neuroimaging and genomic and biomarker data
Number of subjects: 5400
Study 25525693 — intervention group
Group type: EXPERIMENTAL
Intervention: Data and sample repositories
Number of subjects: 5400
Study 25525828 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved biomass stove
Number of subjects: 1415
Study 25525828 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquefied petroleum gas stoves
Number of subjects: 1415
Study 25525828 — intervention group
Group type: COMPARATOR
Intervention: Traditional cooking (control)
Number of subjects: 1415
Study 25526232 — intervention group
Group type: EXPERIMENTAL
Intervention: IBU(Na) 512 mg (equivalent to 400 mg IBU free acid); n = 362
Number of subjects: 891
Study 25526232 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard IBU 400 mg; n = 342
Number of subjects: 891
Study 25526232 — intervention group
Group type: COMPARATOR
Intervention: Placebo; n = 187
Number of subjects: 891
Study 25526776 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6MP) 55 mg/m² per day and methotrexate 15 mg/m² per week
Number of subjects: 30
Study 25526776 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6MP) and methotrexate
Number of subjects: 30
Study 25526948 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced AMD
Number of subjects: 164
Study 25526948 — intervention group
Group type: COMPARATOR
Intervention: Control (no AMD)
Number of subjects: 164
Study 25526948 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (adjusted for age and refractive error)
Number of subjects: 164
Study 25527007 — intervention group
Group type: EXPERIMENTAL
Intervention: wXELIRI (weekly irinotecan 90 mg/m² on day 1 and capecitabine 1200 mg/m² twice daily on days 1-5)
Number of subjects: 52
Study 25527007 — intervention group
Group type: EXPERIMENTAL
Intervention: wXELIRI (weekly irinotecan and capecitabine)
Number of subjects: 52
Study 25527236 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma calprotectin concentrations in T2DM patients
Number of subjects: 305
Study 25527236 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma calprotectin concentrations in T2DM patients with MetS
Number of subjects: 305
Study 25527236 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma calprotectin concentrations in T2DM patients with autonomic neuropathy
Number of subjects: 305
Study 25527236 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma calprotectin concentrations in T2DM patients with peripheral arterial disease (PAD)
Number of subjects: 305
Study 25527236 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma calprotectin concentrations in T2DM patients with myocardial ischemia (MI)
Number of subjects: 305
Study 25527236 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma calprotectin as a predictor of CVD, MI, autonomic neuropathy, or PAD
Number of subjects: 305
Study 25527417 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 40
Study 25527564 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of T cell surface marker expression by flow cytometry and clonality by polymerase chain reaction.
Number of subjects: 4
Study 25527564 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of intracellular cytokines and blood counts over 1-2 months.
Number of subjects: 4
Study 25527564 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow and skin biopsies during different parts of the cycle.
Number of subjects: 4
Study 25527568 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonal heterogeneity in patients with abnormal karyotype
Number of subjects: 1403
Study 25527568 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonal heterogeneity in unfavorable karyotype group
Number of subjects: 1403
Study 25527663 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs)
Number of subjects: 157
Study 25527663 — intervention group
Group type: COMPARATOR
Intervention: Non-users (control group)
Number of subjects: 157
Study 25527677 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-carbohydrate diet
Number of subjects: 99
Study 25527677 — intervention group
Group type: COMPARATOR
Intervention: Lower-fat diet
Number of subjects: 99
Study 25527748 — intervention group
Group type: EXPERIMENTAL
Intervention: VLDL-triacylglycerol 16:1n-7 molar percentage
Number of subjects: 24
Study 25527748 — intervention group
Group type: EXPERIMENTAL
Intervention: DNL index (ratio of 16:0 to 18:2n-6)
Number of subjects: 24
Study 25527748 — intervention group
Group type: EXPERIMENTAL
Intervention: 18:2n-6 levels
Number of subjects: 24
Study 25527752 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fish consumption (≤2.0-3.0 servings/wk)
Number of subjects: 71458
Study 25527752 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish consumption (0.6-2.0 servings/wk)
Number of subjects: 71458
Study 25527752 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean fish consumption (0.6-2.0 servings/wk)
Number of subjects: 71458
Study 25527756 — intervention group
Group type: EXPERIMENTAL
Intervention: CML-AGE consumption (highest quintile)
Number of subjects: 528251
Study 25527756 — intervention group
Group type: EXPERIMENTAL
Intervention: Red meat consumption (highest quintile)
Number of subjects: 528251
Study 25527756 — intervention group
Group type: COMPARATOR
Intervention: CML-AGE consumption (lowest quintile)
Number of subjects: 528251
Study 25527757 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual sleep duration
Number of subjects: 14906
Study 25527759 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitic acid (16:0)
Number of subjects: 3004
Study 25527759 — intervention group
Group type: EXPERIMENTAL
Intervention: Stearic acid (18:0)
Number of subjects: 3004
Study 25527759 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleic acid (18:1n-9)
Number of subjects: 3004
Study 25527759 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccenic acid (18:1n-7)
Number of subjects: 3004
Study 25527759 — intervention group
Group type: EXPERIMENTAL
Intervention: Other fatty acid biomarkers and estimated dietary SFAs or MUFAs
Number of subjects: 3004
Study 25527763 — intervention group
Group type: EXPERIMENTAL
Intervention: 16:1n-9
Number of subjects: 203
Study 25527763 — intervention group
Group type: EXPERIMENTAL
Intervention: 20:3n-6
Number of subjects: 203
Study 25527763 — intervention group
Group type: EXPERIMENTAL
Intervention: 22:5n-3
Number of subjects: 203
Study 25527763 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of 18:2n-6 to 18:3n-3
Number of subjects: 203
Study 25527763 — intervention group
Group type: EXPERIMENTAL
Intervention: 18:3n-3
Number of subjects: 203
Study 25527907 — intervention group
Group type: EXPERIMENTAL
Intervention: RECIST 1.1
Number of subjects: 464